Sent this to Sanford Burnham Prebys Medical Discovery Institute (SBP)
Hi Susan,
Very interesting article on Alzheimers. It is clear that the focus on beta amyloid has been a false path to find an Alzheimer's treatment. The focus on the endoplasmic reticulum is a better path.
Anavex is testing a drug, Anavex 273, which is about to enter p3. In p2 studies, Anavex 273 became the first drug ever given to Alzheimers patients where they actually showed improvement in some cases, and disease stabilization in many.
It works by restoring homeostasis between the mitochondria and the endoplasmic reticulum, so it looks like it works in the ways your research would suggest.
Excellent post, as usual, Falconer. And as Mikesc has kindly pointed out, the well respected medical journalist, Michelle Sullivan, is expected to publish her interview (from yesterday) with Dr Missling sometime today.
Based upon her favorable article from back in FEBRUARY 2017 (link below) regarding the a2-73 safety and efficacy through 57 weeks, I’m curious how she will report on the 109 week IMPROVEMENT/STABILIZATION seen in our Alzheimer’s patients (as correlated to dose/blood concentration per Ariana analysis).
I’m still struggling to find the negatives regarding this Company and its unique and seemingly EFFECTIVE MOA. I’ll keep looking.